Entelos

What Entelos does

Entelos is a provider of predictive biosimulation technology for drug discovery and development, founded in 1996 and headquartered in San Mateo, California. The company's core proposition is the use of computational modeling to simulate biological systems and predict drug responses, intended to serve pharmaceutical and biotechnology R&D organizations seeking to improve candidate selection and reduce late-stage attrition. Historically, Entelos pursued an inorganic growth strategy, acquiring Iconix Biosciences in August 2007 to extend into cheminformatics and toxicology modeling, and Discovery Innovations in May 2005 to broaden its drug discovery technology footprint. The company attracted a roster of life-sciences-specialized investors across multiple private rounds, including Sofinnova Investments, Abingworth, Bear Stearns Health Innoventures, Boulder Ventures, Brentwood Venture Capital, CRV, Earlybird Venture Capital, St. Paul Venture Capital, and later Clearlake Capital Group and Michaelson Capital Partners, raising approximately $39.6 million in disclosed private funding between 2000 and 2013. Entelos was previously listed on the London Stock Exchange under the symbol ENTL but has since been delisted.

The current operational status of Entelos is unclear from available data. The corporate website currently displays only a Cloudflare verification/loading challenge with no accessible product, pricing, or marketing content. No product portfolio, customer logos, pricing model, current management team, partnerships, certifications, headcount breakdown, or recent product launches are documented in the input. The company reports a headcount range of 11-50 employees, but no granular team data is available. No strategic activity — funding, acquisition, product release, partnership, or leadership change — has been documented since June 2013. The market context in which Entelos operates is the broader computational biology market (projected at $6.5B in 2024 growing to $24.2B by 2034 at 14.1% CAGR) and the computational medicine and drug discovery software market (projected at $10.90B in 2025 growing to $60.52B by 2035 at 18.70% CAGR), with the AI-driven drug discovery sub-segment growing at 23.5% CAGR — none of which is company-specific. Given the absence of observable commercial activity for over a decade, delisted equity, and a non-functional website, Entelos appears to be either in extended maintenance mode, effectively dormant, or operating as a residual entity without active commercial scaling.

Name

Entelos

Website

https://entelos.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Entelos provides predictive biosimulation technology for drug discovery and development, serving pharmaceutical and biotechnology R&D organizations. Founded in 1996 and based in San Mateo, California, the company uses computational modeling to simulate biological systems and predict drug responses.

Ownership category

akta.pro rank

Product category

Drug Discovery Software

NAICS

Computer Systems Design Services (541512), Computer Systems Design and Related Services (54151)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Integrated Systems Design (7373)

akta.pro industry

PRIMARYHLAGAFAB

Safety Pharmacology (Cardio/CNS/Respiratory)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

• Predictive biosimulation
• Drug discovery software
• Computational biology
• Pharmacological modeling
• Biotech research services

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Entelos is a provider of predictive biosimulation technology for drug discovery and development. The company builds computational models of biological systems that pharmaceutical clients use to simulate drug behavior, predict efficacy and toxicity, and inform preclinical and clinical decision-making. Through acquisitions of Iconix Biosciences and Discovery Innovations, Entelos extended its capabilities into toxicology and cheminformatics support for pharma R&D programs.

Product overview

No product information available for Entelos in the provided sources. The sources contain only market research reports discussing the computational biology and drug discovery software market broadly, without detailing Entelos's specific product portfolio, architecture, or named offerings.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves5 records

Expansion highlights1 record

Direct peers

• Simulations Plus: Simulations Plus builds biosimulation, PBPK, and quantitative modeling software used across preclinical and clinical drug development, closely paralleling Entelos's predictive biosimulation focus.
• Schrödinger: Schrödinger operates a physics-based computational platform for molecular simulation and drug discovery, directly comparable to Entelos's predictive biosimulation offering and serving the same pharma/biotech R&D buyers.
• OpenEye Scientific (Cadence Design Systems): OpenEye provides computational chemistry and molecular modeling software for drug discovery, comparable to Entelos's predictive simulation capabilities in early-stage discovery workflows.
• Insitro: Insitro applies machine learning to large-scale biological data for drug discovery, sharing Entelos's predictive, data-driven approach to preclinical decision-making.
• Certara: Certara provides model-informed drug development, biosimulation, and regulatory science software — overlapping with Entelos's biosimulation-for-drug-development positioning and targeting the same regulatory-grade modeling use cases.
• Nimbus Therapeutics: Nimbus uses computational chemistry and structure-based design to discover small-molecule therapeutics, sharing Entelos's emphasis on in silico prediction to drive preclinical candidates.
• BenevolentAI: BenevolentAI uses AI and knowledge graphs to accelerate drug discovery, addressing the same R&D productivity problem that Entelos's biosimulation tools target.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI-driven computation to discover drugs — overlapping with Entelos's in silico approach and competing for the same pharma AI-discovery budgets.

Emerging players

• GNS Healthcare: GNS Healthcare uses causal AI and simulation to model disease biology and drug response — directly comparable to Entelos's biosimulation methodology, though focused more on patient-level outcomes data.
• Atomwise: Atomwise applies AI to small-molecule hit discovery, an adjacent but narrower slice of the predictive drug-discovery space where Entelos also operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/entelos
• LinkedInlinkedin.com/company/entelos

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Entelos